⌘K
t
Oxford BioDynamics Plc announced on 05 March 2025 the publication of its annual report and accounts for the year ended 30 September 2024, available electronically on its website and with hard copies being posted to shareholders today. The Company's Annual General Meeting will be held on 28 March 2025 at 10.00 am.
| Date | 5 Mar 2025 |
| Time | 16:00:01 |
| Category | Results |
| ID | 5185Z |
Oxford BioDynamics Plc
("OBD" or the "Company" and, together with its subsidiaries, the "Group")
Publication of 2024 Annual Report
Oxford, UK - 5 March 2025 - Oxford BioDynamics Plc (AIM: OBD, the Company), a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on its EpiSwitch® 3D genomics platform, announces that its annual report and accounts for the year ended 30 September 2024 ("Annual Report") is available in electronic form on its website at www.oxfordbiodynamics.com/investors/financial-results. Hard copies of the report (incorporating the Notice of Annual General Meeting) will be posted to shareholders today.
As stated in the preliminary results announcement on 28 February 2025, the Company's Annual General Meeting will be held at 3140 Rowan Place, John Smith Drive, Oxford Business Park South, Oxford, OX4 2WB, UK on 28 March 2025 at 10.00 am.
-Ends-
For further details please contact:
|
Oxford BioDynamics Plc |
Tel: +44 (0)1865 518910 |
|
Iain Ross Executive Chairman Paul Stockdale, CFO |
|
|
Shore Capital - Nominated Adviser and Broker |
Tel: +44 (0)20 7408 4090 |
|
Advisory: Stephane Auton / Lucy Bowden Broking: Fiona Conroy |
|
|
OAK Securities - Joint Broker |
Tel: +44 (0)20 3973 3678 |
|
Jerry Keen / Henry Clarke / Damion Carruel |
|
|
WG Partners - Joint Broker |
Tel: +44 (0)20 3705 9330 |
|
David Wilson / Claes Spång / Satheesh Nadarajah / Erland Sternby |
|
|
Camarco - Financial PR |
Tel: +44 (0)20 3757 4980 |
|
Marc Cohen / Tilly Butcher / Fergus Young |
Notes to Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) is an international biotechnology company, advancing personalized healthcare by developing and commercializing precision clinical diagnostic tests for life-changing diseases.
Currently OBD has two commercially available products: the EpiSwitch® PSE (EpiSwitch Prostate Screening test) and EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer. CiRT is a highly accurate (85%) predictive response test to immuno-oncology checkpoint inhibitor treatments.
The tests are based on OBD's proprietary 3D genomic biomarker platform, EpiSwitch® which enables screening, evaluation, validation and monitoring of biomarkers to diagnose patients or determine how individuals might respond to a disease or treatment.
OBD's clinical smart tests have the potential to be used across a broader range of indications, and new tests are being developed in the areas of oncology, neurology, inflammation, hepatology and animal health.
The Group's headquarters and UK laboratories are in Oxford, UK. Its US operations and clinical laboratory are in Maryland, USA, along with a reference laboratory in Penang, Malaysia.
OBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more information, please visit the Company's website, www.oxfordbiodynamics.com, X (@OxBioDynamics) or LinkedIn.